RayKnowChina Research Map
Shortlist0

Not yet recruitingOesophageal squamous cell carcinomaPhase 1

Registered title, quoted from ClinicalTrials.gov

Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by West China Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)West China Hospital四川大学华西医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07154108, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed recurrent or metastatic:

    Inclusion criterion 4

    Availability of fresh tumor tissue specimen or pathological slides from the injection target lesion (Cohort B)

    Inclusion criterion 19

  3. Cohort B: ESCC, AJCC 9th edition stage IV

    Inclusion criterion 6

  4. Cohort A: ≥1 prior platinum-based chemotherapy regimen or platinum-refractory/intolerant

    Inclusion criterion 8

    Male/female patients of childbearing potential must use effective contraception during study and for at least 6 months after treatment

    Inclusion criterion 20

  5. ECOG performance status

    Inclusion criterion 13

  6. Cohort A: measurable lesion ≥2 cm by RECIST 1.1

    Inclusion criterion 11

  7. Pregnancy or breastfeeding

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07154108, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

  • Cohort A (Head and Neck Cancer)
  • Cohort B (Esophageal Squamous Cell Carcinoma)

Inclusion Criteria:

  • Age ≥18 years
  • Cohort A (Head and Neck Cancer): ≤70 years
  • Cohort B (Esophageal Squamous Cell Carcinoma): ≤75 years
  • Histologically or cytologically confirmed recurrent or metastatic:
  • Cohort A: Head and Neck Cancer
  • Cohort B: ESCC, AJCC 9th edition stage IV
  • Prior treatment:
  • Cohort A: ≥1 prior platinum-based chemotherapy regimen or platinum-refractory/intolerant
  • Cohort B: Prior immune checkpoint inhibitor (ICI) therapy with documented acquired resistance after prior PR or SD
  • At least one lesion accessible for intratumoral injection
  • Cohort A: measurable lesion ≥2 cm by RECIST 1.1
  • Cohort B: superficial metastatic lymph nodes (cervical or supraclavicular)
  • ECOG performance status
  • Cohort A: 0-2
  • Cohort B: 0-1
  • Adequate organ function
  • Life expectancy ≥12 weeks (Cohort A)
  • No anti-tumor therapy (chemotherapy, radiotherapy, biotherapy, antiviral) within 4 weeks prior to enrollment (Cohort A)
  • Availability of fresh tumor tissue specimen or pathological slides from the injection target lesion (Cohort B)
  • Male/female patients of childbearing potential must use effective contraception during study and for at least 6 months after treatment
  • Voluntary participation with signed informed consent

Exclusion Criteria:

  • Known allergy or hypersensitivity to study drugs
  • Lesions unsuitable for injection due to proximity to major blood vessels, nerves, or hollow organs, or with extensive necrosis
  • Deeply located lesions with high procedural difficulty (Cohort B)
  • Concurrent radiotherapy to target lesion(s) (Cohort A)
  • Prior anti-angiogenic therapy (Cohort A)
  • Immunosuppressive therapy or systemic corticosteroids >10 mg/day prednisone (or equivalent) within 2 weeks prior to enrollment
  • Active autoimmune disease or history of autoimmune disease
  • Congenital or acquired immunodeficiency
  • Severe coagulopathy, bleeding tendency, or high-risk lesions (Cohort B)
  • Poor nutritional status (Cohort B)
  • Interstitial lung disease with symptoms or radiographic evidence (Cohort B)
  • Severe uncontrolled systemic disease or recent myocardial infarction (<3 months)
  • Acute infection
  • Pregnancy or breastfeeding
  • Other malignancy besides ESCC (Cohort B)
  • Patients unlikely to comply with follow-up or participation requirements
  • Any condition deemed unsuitable for enrollment by the investigator

Quoted from ClinicalTrials.gov, NCT07154108, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07154108, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07154108